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Enhanced pharmacological efficacy 
of sumatriptan due to modification 
of its physicochemical properties by 
inclusion in selected cyclodextrins
Magdalena Paczkowska1, Mikołaj Mizera1, Kinga Sałat2, Anna Furgała2, Piotr Popik3, 
Justyna Knapik-Kowalczuk4, Anna Krause5, Daria Szymanowska-Powałowska6, 
Zbigniew Fojud7, Maciej Kozak7, Marian Paluch4 & Judyta Cielecka-Piontek1
The study focused on the pharmacological action of sumatriptan, in particular its antiallodynic and 
antihyperalgesic properties, as an effect of cyclodextrinic inclusion of sumatriptan, resulting in changes 
of its physicochemical qualities such as dissolution and permeability through artificial biological 
membranes, which had previously been examined in vitro in a gastro-intestinal model. The inclusion 
of sumatriptan into β-cyclodextrin and 2-hydroxylpropylo-β-cyclodextrin by kneading was confirmed 
with the use of spectral (fourier-transform infrared spectroscopy (FT-IR); solid state nuclear magnetic 
resonance spectroscopy with magic angle spinning condition, 1H and 13C MAS NMR) and thermal 
(differential scanning calorimetry (DSC)) methods. A precise indication of the domains of sumatriptan 
responsible for its interaction with cyclodextrin cavities was possible due to a theoretical approach to 
the analysis of experimental spectra. A high-performance liquid chromatography with a diode-array 
detector method (HPLC-DAD) was employed to determine changes in the concentration of sumatriptan 
during dissolution and permeability experiments. The inclusion of sumatriptan in complex with 
cyclodextrins was found to significantly modify its dissolution profiles by increasing the concentration 
of sumatriptan in complexed form in an acceptor solution compared to in its free form. Following 
complexation, sumatriptan manifested an enhanced ability to permeate through artificial biological 
membranes in a gastro-intestinal model for both cyclodextrins at all pH values. As a consequence of 
the greater permeability of sumatriptan and its increased dissolution from the complexes, an improved 
pharmacological response was observed when cyclodextrin complexes were applied.
Migraine is one of the most frequent neurological disorders worldwide. The high prevalence of this disabling dis-
ease in the general population generates a strong medical imperative for the search for novel treatment options for 
migraine attacks and its prevention1. Current migraine therapies are mainly non-specific and are characterized 
by low patient compliance. The only specific anti-migraine drugs, i.e. triptans, effectively relieve migraine pain 
but their use is often limited by adverse effects, time-and frequency-restricted application and the risk of devel-
oping medication overuse headache2. In recent years, novel drug targets for migraine have been discovered, e.g. 
5-HT1F receptors and calcitonin-gene-related peptide (CGRP) receptors; however, despite this, the superiority of 
sumatriptan over placebos in the attenuation of headache, nausea, photophobia, and phonophobia in migraineurs 
is still not well-established. Although of the triptans sumatriptan demonstrates the strongest antiemetic action, an 
advantage in the treatment of migraine with vomiting3, it has the lowest bioavailability, which is a limitation to the 
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achievement of a greater pharmacological effect4. Another problem is the bitter taste of sumatriptan that has not 
been eliminated by the conversion of the compound to a succinate ester, a form found in commercially available 
pharmaceutical preparations5. However, the increased lipophilicity of sumatriptan aimed at an enhancement of 
its bioavailability negatively affects its physicochemical properties, such as the required level of solubility, impor-
tant for the development of pharmaceutical formulations.
The pure form of sumatriptan (its base) is a hydrophilic form. After oral administration, this has limited 
absorption and its ability to penetrate biological barriers is insufficient. Similarly, commercially available the 
sumatriptan succinate is not fully absorbed from the gastrointestinal tract, as it is extensively metabolized. Thus, 
sumatriptan succinate also has low bioavailability (about 15%) and a short half-time in the human organism6. 
The aforementioned drawbacks of these two sumatriptan forms do not affect the widespread use of this drug by 
migraine sufferers. Importantly, the significant pharmacological activity of this drug is the premise for the search 
for new triptans and new triptan delivery systems. Taking into consideration the above limitations to the use of 
sumatriptan, cyclodextrins can be viewed as attractive excipients constituting drug delivery systems able to mask 
the taste, increase solubility, and improve bioavailability in oral, nasal and transdermal administration as well 
as allowing for gradual dissolution from the inclusion system ensuring slow drug release7–13. There have been 
reports on the application of some cyclodextrins to obtain intranasal compositions14. All intranasal complexes of 
sumatriptan and cyclodextrins (unsubstituted and substituted) demonstrated improved pharmacokinetic param-
eters (tmax) after nasal administration as a result of greater solubility and bioavailability following the use of com-
plexes. Similar studies on the possibility of applying cyclodextrins as compounds improving physicochemical 
properties important for the oral administration of sumatriptan have not, to the best of our knowledge, been 
published. Reports are available on the development of sumatriptan succinate transdermal delivery systems8–12. 
For example, Balaguer-Fernander obtained transdermal delivery systems of sumatriptan succinate by binding it 
with methyl cellulose, polyvinyl pyrrolidone, and polyvinyl pyrrolidone-polyvinyl alcohol in the presence of a 
required adhesive agent that showed activity when administered on pig ear skin10. Another method of increasing 
the solubility of sumatriptan succinate is by obtaining its amorphous form, for which a higher solubility rate has 
been demonstrated as compared to the crystalline form found in therapeutic applications15. Regarding the advan-
tages of using cyclodextrins to develop oral systems of sumatriptan, the present study required an animal model 
permitting evaluation of the therapeutic effect of the proposed system against the free form of sumatriptan. In 
order to evaluate the possible benefits of preparing a system of cyclodextrin and the acidic form of sumatriptan, 
the pharmacological action of the proposed system was also examined in relation to the salt form, sumatriptan 
succinate, currently used in oral formulations of sumatriptan.
Serotonin 5-HT1B/D receptors have been found on the trigeminal nerve and cranial vessels. Their agonists–
triptans–are effective in migraine attack treatment by acting within the trigeminovascular system to restore nor-
mal serum levels of the calcitonin gene-related peptide (CGRP)16. Since triptans induce vasoconstriction and can 
attenuate neurogenic inflammation by decreasing the release of substance P and CGRP17, in the in vivo part of this 
study we additionally assessed antinociceptive properties of these four forms of sumatriptan in a mouse model 
of neurogenic pain induced by capsaicin. Capsaicin, an active component of chili peppers, is a potent TRPV1 
channel agonist18 and TRPV1 antagonists have been identified as potential therapeutics for migraine19. Capsaicin 
injections stimulate the trigeminovascular system and increase c-fos expression in the trigeminal ganglion in a 
rodent model of migraine19. Apart from its influence on TRPV1, it can regulate CGRP expression in the trigem-
inal ganglion20 and CGRP is strongly involved in capsaicin-induced vasodilation21, being regarded as one of the 
major neuropeptides released from activated trigeminal sensory afferents in headache and facial pain disorders22. 
In migraineurs, CGRP facilitates nociceptive transmission in the activated trigeminovascular system, possibly via 
presynaptic mechanisms23 due to the release of various neurotransmitters, neuropeptides and vasodilators that 
induce severe pain responses.
The aim of the present study was to prepare and characterize a sumatriptan (SUM) inclusion complex with 
β-cyclodextrin (SUM-BCD) and 2-hydroxylpropylo-β-cyclodextrin (SUM-HPBCD) in terms of changes resulting 
from the formation of the complex in the dissolution profiles and permeability of sumatriptan through biological 
membranes in the gastrointestinal tract. In the in vivo part of the present study, the antiallodynic and antihy-
peralgesic properties and related pleiotropic actions of four forms of sumatriptan such as sumatriptan (SUM), 
sumatriptan succinate (SUM-SUCC) and sumatriptan complexes with cyclodextrins (SUM-BCD, SUM-HPBCD) 
were compared after oral administration in a mouse model of migraine pain.
Results
There are three areas of interest regarding the results of the present study: (1) the procedure of identifying 
SUM-BCD and SUM-HPBCD inclusion complexes; (2) the evaluation of the effect of complexation on the disso-
lution and permeability of SUM-BCD and SUM-HPBCD complexes through an artificial membrane simulating 
gastrointestinal permeation as compared to the free form of SUM; (3) the pharmacological (in vivo) antiallodynic 
and antihyperalgesic activity of SUM-BCD and SUM-HPBCD complexes after their oral administration to mice 
as compared to both the free form of SUM and its commercially available ester form.
SUM-BCD and SUM-HPBCD inclusion complexes were obtained by co-grinding method. Their formation 
was a spontaneous, repeatable process. The presence of inclusion complexes was confirmed by using spectro-
scopic (Fourier transform infrared spectroscopy, FT-IR; solid state nuclear magnetic resonance spectroscopy with 
magic angle spinning condition, 1H and 13C MAS NMR) and thermal (differential scanning calorimetry, DSC) 
and methods.
The types of bands, their location and intensity were determined for a SUM molecule in free form and com-
pared with theoretical spectra based on quantum-chemical calculations performed with the use of the B3LYP 
functional and 6–31 G(d, p) as a basis set. A theoretical analysis, based on a simulation of molecular docking, sug-
gested that, for the SUM-BCD and SUM-HPBCD complexes, inclusion occurred of an H-indol-5-yl structure and 
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a dimethylaminoethyl group with a stronger retention of the phenyl ring in the HPBCD cavity (Fig. 1). The spec-
troscopic (FT-IR) analysis showed a marked decrease in the intensity of bands corresponding to an H-indol-5-yl 
domain or their disappearance in the following ranges corresponding to particular types of vibration and specific 
bonds: 600–850 cm−1, the bending vibrations of C-C-C; 640 cm−1, the wagging vibrations of C-H; 777 cm−1, the 
stretching vibrations of C-C and C-H; 830 cm−1, and the bending vibrations of C-C-H; 1400–1500 cm−1, the 
stretching vibrations of C-N; 1400–1500 cm−1, the deformation vibrations of C-C; 1392 cm−1, the bending vibra-
tions of C-N-H; at 1457 cm−1, the skeleton vibrations of C-H; 1514 cm−1, the stretching vibrations of C-C and 
the wagging vibrations of C-H. The changes in band intensity in the range 1000–1300 cm−1 and the considerably 
reduced band intensity at 1460 cm−1 were attributed to the interaction of the dimethylaminoethyl group with 
the cyclodextrins. The most significant changes in band intensity were those corresponding to the wagging and 
twisting vibrations of the C-H bonds located at 1155 cm−1, 1183 cm−1 and 1333 cm−1. The band that differenti-
ated the complexes of sumatriptan and the cyclodextrins relative to the dimethylaminoethyl group occurred at 
1460 cm−1 and corresponded to the twisting vibrations of the C-H bond. In the SUM-HPBCD complexes, this 
band disappeared confirming the results of theoretical studies that suggested the stronger impact of the dimethyl-
aminoethyl group toward the HPBCD cavity. All spectra are collected in Fig. 1. The changes described above were 
not observed for the physical mixture of SUM-BCD and SUM-HPBCD.
Thermal properties of SUM, BCD, HPBCD, SUM-BCD and SUM-HPBCD were investigated by DSC. This 
technique enables the determination of presence or absence of the drug-melting endotherm, which might finally 
verify if the active pharmaceutical ingredient (API) was successfully complexed in CDs24,25. The DSC thermo-
grams (obtained during heating–HR = 10 °C min−1) of SUM, BCD, HPBCD and binary systems of SUM-BCD 
and SUM-HPBCD are shown in Fig. 2. As can be seen, neat SUM exhibits a melting peak with an onset at 
175 °C (ΔHfus = 144.4 J g−1) which is typical for anhydrous crystalline drugs. The DSC traces of both BCD and 
HPBCD reveal a very broad endothermal peak located between 60 °C and 140 °C for BCD, and between 40 °C to 
120 °C for HPBCD, related to the loss of water. In the case of the investigated formulations, i.e. SUM-BCD and 
SUM-HPBCD, two endothermic processes were registered during DSC measurements. The first, with the max-
imum located at 113 °C for SUM-BCD and at 83 °C for SUM-HPBCD, reflects water evaporation from the sam-
ples; and the second, smaller endothermic peak with an onset at 172 and 146 for SUM-BCD and SUM-HPBCD, 
respectively, corresponds to the melting point of SUM.
The solid state NMR with magic angle spinning (MAS) experiments were performed on two nuclei 1H and 13C. 
This extremely powerful method was widely used in studies of structure of complex macromolecular system in 
solid state including synthetic and natural polymers, surfactants as well as drug delivery systems26. The solid state 
NMR studies were recently used in the studies of some inclusion compounds based on cyclodextrin systems27,28. 
Therefore this method was selected as an additional tool to confirm the formation the sumatriptan/cyclodextrin 
inclusion compounds. The 1H and 13C NMR MAS spectra are presented in Fig. 3. In these comparison of spectra 
recorded for all studied complexes as well as reference substances are clearly visible characteristic changes in spec-
tra of both complexes studied. These spectra are different from only superposition of signals from reference com-
pound, which is a direct confirmation of formation of hydrogen bonds and formation of stable complexes. The 
most important changes are observed on the 13C spectrum in the ppm region from 50 to 60, where the broader 
band appeared. This band broadening ascribed to the formation of new rigid network as a result of interactions 
between cyclodextrin wall and included compound (SUM).
Figure 1. FT-IR absorption spectra for SUM, BCD, SUM-BCD, HPBCD and SUM-HPBCD inclusion complexes.
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An HPLC-DAD method with the isocratic flow of the mobile phase was developed to determine the con-
centrations of sumatriptan during studies of dissolution profiles and permeability. The method was validated 
according to ICH guidelines29. Additionally, to confirm the absence of SUM degradation during the preparation 
of the inclusion complex, an HPLC-DAD method with a gradient mobile phase was applied, which permitted 
determination of all impurities30.
The dissolution profiles of SUM and the SUM-BCD and SUM-HPBCD inclusion complexes were compared in 
simulated gastric fluids (pH 1.2) and phosphate buffer (pH 4.5 and 6.8) (Fig. 4). The similarity of the dissolution 
profiles of SUM, SUM-BCD and SUM-HPBCD was evaluated statistically on the basis of the Moore and Flanner 
model31. The similarity between the dissolution percentages of SUM in different forms was established based on 
parameters f1 and f2 and defined by the following equations:
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in which n is the number of withdrawal points, Rj-the percentage of the dissolved reference compound at time 
point t, Tj-the percentage of dissolved SUM-BCD or SUM-HPBCD at time point t.
According to this model and for all tested values of pH, the difference factor f1 exceeded 15 and the f2 factor 
was below 50, which reflected major differences between SUM, SUM-BCD and SUM-HPBCD complex dissolu-
tion profiles as well as the strong influence of cyclodextrins on the rate of SUM dissolution.
The second aspect of interest regarding the influence of cyclodextrins on SUM as a result of complexation 
comprised changes in the permeability of SUM through an artificial membrane in a model of the gastro-intestinal 
tract. This was assessed against a reference standard that was the permeability of SUM in free form. The apparent 
permeability coefficient (Papp) was calculated from the following equation:
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Figure 2. DSC thermograms of: neat SUM (upper panel); neat BCD (lower trace on the lower left panel); neat 
HPBCD (lower trace on the lower right panel); SUM-BCD (upper trace on the lower left panel); SUM-HPBCD 
(upper trace lower right panel).
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where VD–donor volume, VA–acceptor volume, Cequilibrium–equilibrium concentration =
× + ×
+
Cequilibrium
C V C V
V V
D D A A
D A
, 
CD–donor concentration, CA–acceptor concentration, S–membrane area, t–incubation time (in seconds).
The permeability of SUM in complexed forms (SUM-BCD and SUM-HPBCD) and in free form was studied 
for the gastrointestinal tract using a PAMPA system at three values of pH: 1.2, 4.5 and 6.8 (Fig. 5). Apparent 
permeability coefficients were found for all systems under study. To verify that Papp determined for permeability 
was statistically different, an ANOVA test was used. Compounds with Papp < 1 × 10−6 cm s−1 are classified as 
low-permeable and those with Papp > 1 × 10−6 cm s−1 as high-permeable compounds. All systems showed low val-
ues of apparent permeability coefficients under all study conditions. Following the formation of complexes with 
cyclodextrins, a statistically significant improvement was found in the permeability of SUM through the mem-
brane structures of the gastrointestinal tract model (PAMPA). Increased permeability was observed in all acceptor 
systems. A twofold rise in permeability occurred during the inclusion of SUM into HPBCD ((0.16 ± 0.01) × 10– 6 
cm s−1 and (0.40 ± 0.02) × 10−6 cm s−1 at pH 1.2, (0.17 ± 0.03) × 10–6 cm s−1 and (0.52 ± 0.03) × 10−6 cm s−1 at pH 
4.5, (0.16 ± 0.02) × 10–6 cm s−1 and (0.49 ± 0.02) × 10−6 cm s−1 at pH 6.8 for SUM and SUM-HPBCD complexes, 
respectively).
As a result of a considerable increase in the solubility and permeability of SUM after its incorporation into 
the cyclodextrins systems, a decision was taken to continue the study in an in-vivo model, where an additional 
reference (alongside SUM in free form) was a study of the analgesic effect of sumatriptan succinate available in 
commercial preparations.
During in vivo studies in the von Frey test, an overall effect of treatment was observed for sumatriptan (F[5, 
54] = 35.60, p < 0.001). The dose 0.6 mg kg−1 attenuated tactile allodynia significantly (p < 0.001), but a lower dose 
Figure 3. 1H spectra in liquid (A,B), 1H spectra in solid (C) and 13C spectra in solid (D) of SUM, SUM-BCD 
inclusion complex, and SUM-HPBCD inclusion complex.
Figure 4. Dissolution profiles for SUM, SUM-BCD physical mixture, SUM-BCD inclusion complex, SUM-
HPBCD physical mixture and SUM-HPBCD inclusion complex in artificial gastric juice at pH 1.2, in phosphate 
buffer at pH 4.5 and in phosphate buffer at pH 6.8.
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was not active (Fig. 6A). An overall effect of treatment was also observed for sumatriptan-BCD (F[5, 51] = 30.53, 
p < 0.0001). Post hoc analysis revealed that the antiallodynic effect was significant (p < 0.001) only for the dose of 
0.6 mg kg−1 (Fig. 6A). SUM-HPBCD and sumatriptan succinate significantly affected tactile allodynia in this pain 
model (F[5, 48] = 23.04, p < 0.001; F[5, 54] = 79.57, p < 0.001, respectively). Statistically significant antiallodynic 
properties were demonstrated for both doses of these two sumatriptan forms (Fig. 6A).
In the hot plate test, an overall effect of treatment was observed for sumatriptan (F[5, 51] = 3.082, p < 0.05). 
However, post hoc analysis did not show significant differences between measured pre-drug and post-drug laten-
cies (Fig. 6B). For SUM-BCD and SUM-HPBCD, no overall effect of treatment was observed in the hot plate test 
(F[5, 54] = 0.88, p > 0.05 for SUM-BCD and F[5, 45] = 1.900, p > 0.05 for SUM-HPBCD, Fig. 5B). In this assay, 
an overall effect of treatment was observed for sumatriptan succinate (F[5, 48] = 3.00, p < 0.05), but no significant 
differences between pre-drug and post-drug latencies were observed for either dose of this drug form (Fig. 6B).
In the neurogenic pain model induced by capsaicin administration, an overall effect of treatment was observed 
(F[8, 53] = 2.152, p < 0.05), but the post hoc analysis of results obtained for drug-treated groups compared to 
vehicle-treated mice showed no significant differences between groups (Fig. 7).
Discussion
The inclusion complexes SUM-BCD and SUM-HPBCD (1:1) were obtained by co-grinding method. The inclu-
sion was a spontaneous process requiring no use of organic solvents, which eliminated the need to dispose of 
or control their volatile residues. Equally importantly, such a process is easily scalable. A similar phenomenon 
of spontaneous and permanent inclusion has been observed for other active pharmaceutical substances32,33. 
Spectroscopic (FT-IR, NMR) and thermal (DSC) methods were used to confirm the identity of the complexes. 
The use of the FT-IR method based on a theoretical approach to the determination of theoretical spectra and the 
application of docking to propose the domains involved in the interaction with the cyclodextrins made it possible 
to accurately obtain the SUM structures directly involved in interactions with the inside of a cyclodextrin cavity. 
Hydrophobic domains such as the H-indol-5-yl structure and the dimethylaminoethyl group were indicated as 
the incorporated ones. During interactions with HPBCD, the dimethylaminoethyl group was more involved in 
interaction with the cyclodextrin cavity.
Thermal analysis of the investigated systems reveals that both SUM-BCD and SUM-HPBCD formulations 
possess some free SUM (not trapped inside CD). This is evidenced by the presence of the small peak with an onset 
at 172 °C and 146 °C for SUM-BCD and SUM-HPBCD, respectively. These endothermal peaks originate from the 
melting of free SUM existing in the examined binary compositions. From the comparison of the fusion enthalpies 
of the neat API and the mixtures, it was possible to estimate the degree of CD inclusion. Knowing (1) the molecu-
lar weight of all components as well as (2) the weight percentage of SUM in the formulations, one might calculate 
the enthalpy of fusion of the ideal systems in which there is no inclusion (29.8 J g−1 and 25.2 J g−1 for SUM-BCD 
and SUM-HPCD, respectively). Comparing these–calculated–values to the experimental data, it was possible to 
estimate that, in the SUM-BCD formulation, 19.8% of SUM is trapped inside BCD, while in the SUM-HPBCD 
formulation CD inclusion by SUM is equal to 58.3%.
Figure 5. Apparent permeability coefficient for SUM, SUM-BCD physical mixture (abbr. “m.”), SUM-BCD 
complex (abbr. “c.”), SUM-HPBCD physical mixture and SUM-HPBCD complex in artificial gastric juice at pH 
1.2, in phosphate buffer at pH 4.5 and in phosphate buffer at pH 6.8.
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As presented in Fig. 3 the characteristic changes in NMR spectra, especially in 13C NMR, the formation of 
inclusion compound has been confirmed. The broadened band at 60 ppm exhibits the formation of hydrogen 
bond to the cyclodextrin OH groups and hindered or even blocked the rotation of CH2 group located between 
sulfodixide and H-indol-5-yl structure fragments of SUM.
According to the dissolution profiles, the inclusion complexes SUM-BCD and SUM–HPBCD demonstrated 
superior release characteristics in simulated intestinal fluids for all pH values (1.2, 4.5 and 6.8). In the case of 
SUM-BCD and SUM-HPBCD, the slightest improvement in solubility was registered at pH 1.2. Under such con-
ditions, SUM was also characterized by the lowest solubility. The considerably better solubility of both cyclo-
dextrin complexes was observed and resulted in the different shapes of their dissolution profiles. The increased 
solubility of sumatriptan could be explained by the inclusion into the cyclodextrins of its two hydrophobic 
domains: the H-indol-5-yl structure and the dimethylaminoethyl group. The presence of a greater number of 
hydrophilic groups on the surface of HPBCD was responsible for the superior solubilization of sumatriptan in 
the case of its inclusion into the complex. This process was intensified by the stronger retention of the dimeth-
ylaminoethyl group inside the HPBCD complex. These results correspond to those published in reports on the 
Figure 6. Influence of SUM forms on tactile allodynia (A) and thermal hyperalgesia (B) in a mouse model of 
migraine pain induced by nitroglycerin (NTG) administration. Results are shown as mean paw withdrawal 
forces (±SEM) measured in the von Frey test (A), or latency time to pain reaction (±SEM) measured in the hot 
plate test (B) for n = 8–10. Statistical analysis: analysis of variance (ANOVA), followed by Tukey’s post hoc test. 
Significance vs. baseline (i.e. before nitroglycerin administration) paw withdrawal force, or latency time to pain 
reaction: #p < 0.05, ###p < 0.001. Significance vs. pre-drug (i.e. before SUM form administration) measurement: 
*p < 0.05, ***p < 0.001.
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use of cyclodextrins as release modifiers for certain molecules, which have confirmed the significant potential of 
cyclodextrins as excipients in this respect34,35. For example, the solubility of naringenin has been found to increase 
twofold after its inclusion into a cyclodextrin36. In the case of capsaicin, the rise in solubility following inclusion 
into HPBCD is markedly greater compared to its interactions with BCD35.
The permeability experiments also showed significant differences in the apparent permeability coefficient for 
complexed SUM in relation to its free form. An approximately 25% increase was observed for the SUM-BCD 
complexes and an over twofold rise within the entire pH range studied for SUM-HPBCD. As demonstrated 
by Warner, SUM is absorbed throughout the gastrointestinal tract and its absorption is similar after oral and 
jejunal administration, and less after cecal administration37. The increased permeability of sumatriptan is most 
certainly a consequence of its greater solubility due to inclusion into cyclodextrins. According to Loftsson, the 
improved dissolution of drugs in aqueous gastrointestinal fluids causes diffusion toward the mucosal surface and 
better immediate absorption38. Enhanced bioavailability resulting from the formation of inclusion complexes 
has been reported for a number of drugs whose poor solubility reduced their absorption39. Limited function-
ality of cyclodextrins in relation to compounds requiring transport systems for absorption through biological 
membranes that rely on phenomena other than passive diffusion as well as the lower bioavailability of drugs 
in which inclusion comprises their hydrophobic domains40. There have been many reports indicating that the 
inclusion of a drug into a cyclodextrin enhances its bioavailability41. For instance, acyclovir in a complex with 
hydroxypropyl-β-cyclodextrin has shown promising results regarding oral therapy for the treatment of herpes 
viruses42. With respect to the present work, the increased solubility of sumatriptan achieved by inclusion compl-
exation with cyclodextrins ensured the drug’s better dissolution in all regions of the gastrointestinal tract, result-
ing in greater permeability and, probably, bioavailability. Previous studies have demonstrated that sumatriptan 
is absorbed poorly but rapidly, which explains the enhancement of permeability for all pH values studied as a 
result of an increase in the concentration of dissolving SUM over a short period of time in the case of cyclodextrin 
systems43. The bioavailability of sumatriptan upon oral administration is also limited by the effect of first-pass 
metabolism and amounts to approx. 14% (Scott 1994). Efforts to eliminate the aforesaid effect have included the 
development of intranasal and buccal forms of sumatriptan succinate44,45. Shivanand demonstrated the possibility 
of increasing the bioavailability of sumatriptan succinate following buccal administration45. The literature also 
refers to enhancement of the bioavailability of some active substances due to the part played by cyclodextrin com-
plexes in the saturation of enzymes involved in the first-pass metabolism. Substances in cyclodextrin complexes 
have been found to dissolve more rapidly. Therefore, their absorption can lead to enzyme saturation during their 
first pass through the liver, resulting in a higher fraction of unmetabolized drugs entering the systemic circula-
tion compared to the situation with substances in free form with a lower dissolution rate. The results obtained 
within the scope of the present study, indicating an improvement in the solubility of sumatriptan and an increase 
in its permeability through artificial membranes simulating the gastrointestinal tract across the whole pH range, 
formed the basis for further experiments on an animal model.
In the in vivo part of the present study, we compared anti-migraine pain properties of two novel forms of 
SUM complexed with cyclodextrins (SUM-BCD and SUM-HPBCD) with classic sumatriptan in a base form and 
sumatriptan succinate. To assess the antiallodynic and antihyperalgesic properties of these orally administered 
forms of sumatriptan, we used a mouse model of migraine pain induced by nitroglycerin. Nitroglycerin is a 
donor of nitric oxide which is a molecule implicated in migraine pathogenesis and migraine-associated hyper-
sensitivity46. In laboratory animals, intraperitoneally administered nitroglycerin may trigger migraine-like pain, 
so it could induce key behavioral responses (tactile allodynia and thermal hyperalgesia) that resemble migraine 
Figure 7. Antinociceptive activity of SUM forms in the capsaicin-induced neurogenic pain model in mice. 
Results are shown as duration of the licking/biting response (±SEM) for n = 6–9. Statistical analysis: one-way 
analysis of variance, followed by Dunnett’s post hoc comparison. Results were not significant (p > 0.05).
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symptoms in humans. The dose of nitroglycerin was chosen based on previous reports that demonstrated a rapid 
development of allodynia without any undesirable effect on systemic blood pressure34.
During the headache phase in migraine, mechanical allodynia is the most prominent symptom and stimuli 
that are normally innocuous are detected as painful. Migraineurs experience increased sensitivity to non-noxious 
thermal and mechanical stimulation and cutaneous allodynia in these patients is a clinical manifestation of 
central nervous system sensitization47. Migraine-related skin hypersensitivity occurs both in trigeminal and at 
extracephalic sites19. Therefore, in our in vivo research we focused on the effect of sumatriptan forms on tactile 
allodynia and we used the von Frey test as a well-established assay to measure antiallodynic properties of the 
drugs tested. In line with previous studies, the injection of nitroglycerin induced mechanical allodynia which was 
sensitive to acute migraine therapy using all forms of sumatriptan; however, it was only for sumatriptan-HPBCD 
and sumatriptan succinate that the dose of 0.3 mg kg−1 was effective.
Our present research that utilized nitroglycerin failed to establish any effect of sumatriptan forms on heat 
hyperalgesia. There might be several reasons to explain the inability of nitroglycerin to induce thermal hypersen-
sitivity. Firstly, in contrast to other authors who tested sumatriptan on C57BL/6J mice, we used a distinct mouse 
strain48. Secondly, the hot plate test is an assay for the detection of pain of central origin and it assesses nocifensive 
responses at the supraspinal level, so it might not be able to reveal peripheral pain responses49. Thermal hyper-
algesia in migraine models might be related to peripheral inflammation and sumatriptan was able to attenuate 
thermal hypersensitivity induced by intraplantar injection of carrageenan but it had no effect on thermal hyperal-
gesia caused by sciatic nerve injury50. This differential effect might be explained in terms of the distinct responses 
of sensory neurons in inflammatory and neuropathic pain conditions, which leads to distinct mechanisms that 
underlie the development of thermal hyperalgesia in these two pain states.
To further investigate the anti-migraine properties of sumatriptan forms, we implemented the capsaicin test. 
The role of TRPV1 and capsaicin-sensitive fibers in migraine is still controversial, but it has been demonstrated 
that capsaicin is a potent stimulant of the trigeminovascular system and is responsible for the release of CGRP, a 
key mediator in migraine pain51. The release of CGRP from capsaicin-sensitive trigeminal sensory nerves dur-
ing migraine attacks results in cranial vasodilatation and central nociception; hence, trigeminal inhibition may 
prevent this vasodilatation and attenuate migraine headache52. The anti-migraine properties of triptans may be 
due to vasoconstriction of the carotid arterial bed via 5-HT1B receptors and the inhibition of CGRP release from 
trigeminal nerves via 5-HT1B/D receptors, in our study sumatriptan forms were inactive in the capsaicin test. This 
lack of efficacy of sumatriptan in this test is, at least to some degree, in line with the results obtained by other 
authors who have shown that intravenous sumatriptan is not effective in the inhibition of capsaicin-induced 
responses related to cranial vasodilatation and central nociception53.
Experimental
Materials for in vitro studies. Sumatriptan and sumatriptan succinate (purity > 98%) were supplied by 
Pharmachem International Co. (China). β-Cyclodextrin (purity > 98%) and 2-hydroxylpropylo-β-cyclodex-
trin were obtained from Sigma-Aldrich (Poland). Acetonitrile of UHPLC grade was supplied by Merck KGaA 
(Germany). Formic acid (100%), hydrochloric acid and potassium dihydrogen phosphate were obtained from 
Avantor Performance Materials (Poland). High-quality pure water was prepared using a Millipore Exil SA. 67120 
purification system.
Preparation of the cyclodextrin inclusion complex. The solid inclusion complex of sumatriptan 
(SUM) with β-cyclodextrin (BCD) and 2-hydroxylpropylo-β-cyclodextrin (HPBCD) was obtained by the 
co-grinding method. Co-ground SUM-BCD and SUM-HPBCD were prepared by ball-milling the SUM and BCD 
or HPBCD in the same molar ratio 1:1 in a ball mill (Retsch MM400) at a frequency of 30 Hz for 60 minutes. The 
cyclodextrin complexes were kept in an atmosphere of controlled humidity at 45% RH.
Characterization of the SUM-BCD and SUM-HPBCD inclusion complexes. During identification 
studies of the SUM-BCD and SUM-HPBCD complexes, spectroscopic (FT-IR, NMR) and thermal (DSC) tech-
niques were used. An HPLC-DAD method was applied for the measurement of SUM concentration changes 
during studies of dissolution and permeability through biological membranes.
Spectroscopic analysis. SUM and SUM-BCD and SUM-HPBCD inclusion complexes were obtained separately 
with IR grade potassium bromide at the ratio of 1:100, and IR pellets were prepared by applying 8 metric tons of 
pressure in a hydraulic press. The vibrational infrared spectra were measured between 500 and 1800 cm−1 with an 
FT-IR Bruker Equinox 55 spectrometer equipped with a Bruker Hyperion 1000 microscope. In order to analyze 
positions and intensity of bands in experimental spectra of SUM, quantum-chemical calculations were performed 
based on B3LYP functional and 6–31 G(d, p) as a basis set. All the calculations were made using the Gaussian 09 
package and the GaussView application54. While for prediction of the interactions of SUM and CD, theoretical 
research was conducted which presented the most provisional places of SUM inclusion into the cyclodextrin 
cavity.
Theoretical analysis. Theoretical studies were conducted with the application of docking and molecular mod-
eling approaches. The SUM as well as macromolecule geometries were optimized using Density Functional 
Theory (DFT) with a hybrid functional B3LYP (Becke, 3-parameter, Lee-Yang-Parr) and 6–31 G(d, p) basis set. 
AutoDock Vina was used to find optimal binding modes of SUM–CD inclusion complexes. The geometries of 
most energetically favored binding modes were fine-tuned by a search for the lowest energy in respect to ligand 
rotation inside the CD cavity. Parameterized Method 6 was used to optimize geometry in systems with ligands 
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rotated in a range from 0–180°. The binding energy of the most energetically favored binding mode at PM6 level 
of theory was calculated with the DFT B3LYP 6–31 G(d, p) method with Basis Set Superposition Error correction.
Thermal analysis. Thermal properties of neat SUM, BCD, HPBCD as well as inclusion complexes SUM-BCD 
and SUM-HPBCD were examined using a Mettler-Toledo DSC 1 STARe System. The measuring device was 
calibrated for temperature and enthalpy using zinc and indium standards. The instrument was equipped with an 
HSS8 ceramic sensor with 120 thermocouples and a liquid nitrogen cooling station. Samples of about 5 mg were 
measured in an ehaviour crucible (40 μL). All measurements were performed in a range from 30 °C to 190 °C with 
a heating rate equal to 10 °C min−1.
NMR analysis. The NMR studies were performed by the use of NMR Agilent 400 MHz spectrometer and Wide 
Bore Triple Resonance T3 MAS XY{1H-19F} probe head. 13C experiment was performed using the standard one 
pulse sequence with the decoupler mode with TPPM (two pulses phase modulation) schema. For each sample, 
loaded in ZrO2 4-mm spinner, the NMR spectrum collected was a result of NS = 1024 accumulations, collected 
every 60 seconds with the spinning rate 5 kHz. 1H solid-state NMR spectra were recorded in the same conditions 
with single pulse sequence of NS = 16 and repetition time 60 s.
Studies of the physicochemical properties of the SUM-BCD and SUM-HPBCD inclusion com-
plexes. The changes in SUM concentrations during dissolution and permeability through artificial biologi-
cal membranes of the gastro-intestinal tract were determined using the HPLC-DAD method. The HPLC-DAD 
method with an isocratic mobile phase was developed and validated. The determination of SUM was possible 
using an LC system (Dionex Thermoline Fisher Scientific, Germany) equipped with a high pressure pump 
(UltiMate 3000), an autosampler (UltiMate 3000) and a DAD detector (UltiMate 3000) with Chromeleon soft-
ware version 7.0 from Dionex Thermoline Fisher Scientific (US). Separations were performed on a Kinetex C-18 
(100 mm × 2.10 mm, 2.6 µm) column. The detection of SUM was performed using a diode array detector at a 
wavelength maxima (𝜆max) of 282 nm. The mobile phase consisted of a mixture of 0.1% formic acid and acetoni-
trile (80:20 V/V) with a mobile phase flow rate of 0.5 mL min−1. The column was set at 30 °C. For determination 
of the impurities of SUM which can be formed during the formation of its cyclodextrins complexes, HPLC-DAD 
was applied with a gradient mobile phase.
Dissolution studies of SUM and SUM-BCD and SUM-HPBCD inclusion complexes. Dissolution 
studies of SUM from SUM-BCD and SUM-HPBCD inclusion complexes were performed using a standard paddle 
Agilent 708-DS Dissolution Apparatus with a 500-mL dissolution medium at 37 ± 0.5 °C and 50 rpm for 120 min. 
Samples were weighted into gelatin capsules and then were placed in a spring to prevent flotation of the capsule on 
the surface of the liquid. As dissolution media, artificial gastric juice at pH 1.2 and phosphate buffer at pH 4.5 and 
6.8 were used. At appropriate time intervals, dissolution samples (5.0 mL) were collected with the replacement of 
equal volumes of temperature-equilibrated media. Samples were then filtered through a 0.45 μm membrane filter.
Permeability studies of SUM and SUM-BCD and SUM-HPBCD inclusion complexes. Differences in the gas-
trointestinal permeability of SUM, SUM-BCD and SUM-HPBCD physical mixtures, and SUM-BCD and 
SUM-HPBCD complexes were investigated by using a PAMPA method (parallel artificial membrane permeability 
assay). The system consisted of a 96-well microfilter plate and a 96-well filter plate and was divided into two cham-
bers: a donor at the bottom and an acceptor at the top, separated by a 120-μm-thick microfilter disk coated with a 
20% (w/v) dodecane solution of a lecithin mixture (Pion, Inc.). The donor solution was adjusted to pH 1.2, 4.5 and 
6.8. The SUM, SUM-BCD and SUM-HPBCD were dissolved in the donor solution. The plates were put together 
and incubated at 37 °C for 2 h in a humidity-saturated atmosphere. The concentrations of SUM, SUM-BCD and 
SUM-HPBCD in the donor and acceptor compartments were determined using the HPLC-DAD method.
In vivo studies. Chemicals used for in vivo assays. For in vivo tests, the compounds were prepared in 1% 
Tween 80 solution (Polskie Odczynniki Chemiczne, Poland) and they were administered by the oral route. To 
perform quantitative comparison of the antiallodynic, antihyperalgesic and antinociceptive activities of drugs 
to be tested, we selected two doses for each form of sumatriptan. These doses corresponded to those found in 
the available literature about sumatriptan (0.3 and 0.6 mg kg−1, oral route). Control mice received 1% Tween 80. 
Nitroglycerin (Perlinganit, 1 mg 1 mL−1, UCB Pharma GmbH, Germany) was administered by the intraperitoneal 
route 45 min before ehavioural tests. Capsaicin was provided by Sigma Aldrich (Poland). For the in vivo experi-
ments, this capsaicin was dissolved in ethanol (100%) at 5% of the final desired volume and then 0.9% saline was 
added. This mixture was vortexed for 10 min55.
Animals and housing conditions. In in vivo tests, adult male Albino Swiss (CD-1) mice weighing between 
18–22 g were used. The animals were purchased from the Animal Breeding Farm of the Jagiellonian University 
in Kraków. The animals were housed in groups of 10 mice per cage at a room temperature of 22 ± 2 °C, under a 
light/dark (12:12) cycle. The animals had free access to food and tap water before experiments. Both the ambient 
temperature of the experimental room and humidity (50 ± 10%) were kept constant throughout all the tests. 
For ehavioural experiments, the animals were selected randomly. Each experimental group consisted of 6–10 
animals/dose. The experiments were performed between 9:00 AM and 2:00 PM. Immediately after the in vivo 
assays, the animals were euthanized by cervical dislocation. All procedures were approved by the Local Ethics 
Committee of the Jagiellonian University in Kraków (7.12.2017) and the treatment of animals was in full accord-
ance with ethical standards laid down in respective Polish and EU regulations (Directive No. 86/609/EEC).
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Nitroglycerin-induced migraine-like pain model. Induction phase: In order to develop migraine-like pain in 
mice, the animals were injected intraperitoneally with a single dose of nitroglycerin (10 mg kg−1)56. To assess the 
influence of the test drugs on tactile allodynia and heat hyperalgesia, the pain sensitivity threshold of experimen-
tal animals was assessed using the von Frey test and the hot plate test, respectively. Measurements were collected 
before nitroglycerin administration (referred to as “before nitroglycerin”), 45 min after its injection (baseline, 
pre-drug measurement) and then 45 min after sumatriptan administration (post-drug measurement).
Influence on tactile allodynia (von Frey test): Mechanical hypersensitivity (tactile allodynia) in mice was 
assessed using an electronic von Frey unit (Panlab, Spain) supplied with a single flexible filament applying 
increasing force (from 0 to 10 g) against the plantar surface of the hind paw of a mouse. The nocifensive paw 
withdrawal response automatically turned off the stimulus and the mechanical pressure that evoked the response 
was recorded. On the day of the experiment, the mice were placed in individual test compartments with a wire 
mesh bottom and were allowed to habituate for 30 min. After the habituation period, each mouse was tested 
3 times alternately in each hind paw, allowing at least 30 s between each measurement. Then, the mice were 
pretreated with nitroglycerin and 45 min later the animals were tested again for their pain sensitivity threshold 
(pre-drug measurement)57. This procedure was also repeated 45 min after sumatriptan administration (post-drug 
measurement).
Influence on thermal hyperalgesia (hot plate test). Immediately after the von Frey test, the antihyperal-
gesic properties of sumatriptan forms were assessed in the hot plate test according to a slightly modified 
method as previously described58. The hot plate apparatus (Hot/cold plate, Bioseb, France) is supplied with a 
temperature-controller that maintains surface temperature to a set point (here 55–56 °C). In this assay, the ani-
mals were first tested to obtain baseline latencies to pain reaction (licking hind paws or jumping) before nitro-
glycerin injection (referred to as latencies “before nitroglycerin”). Then, nitroglycerin was injected and latencies 
to pain reactions were measured again (referred to as “pre-drug latencies”). Subsequently, test drugs were admin-
istered and post-drug latencies were measured again. In this assay, a cut-off time of 60 s was established to avoid 
potential paw tissue damage and animals not responding within 60 s were removed from the apparatus and 
assigned a score of 60 s.
Capsaicin-induced neurogenic pain model. Capsaicin tests were performed 60 min after the administration of 
test compounds or vehicle. After the adaptation period (15 min), 1.6 μg of capsaicin dissolved in 20 μL of a mix-
ture containing 0.9% saline and ethanol (5% of the final volume) was injected intraplantarly in the ventral surface 
of the right hind paw of each mouse. The animals were observed individually for 5 min following capsaicin injec-
tion. In all experimental groups, the duration of the nocifensive behavior, i.e. the amount of time spent on licking, 
biting or lifting the injected paw, was recorded with a chronometer and this was compared between drug-treated 
and vehicle-treated groups52.
Data analysis. Data analysis of the results obtained in behavioral tests was provided by GraphPad Prism 
Software (v.5, CA, USA). The results were statistically evaluated using analysis of variance (ANOVA), followed by 
Tukey’s or Dunnett’s post hoc comparisons. P < 0.05 was considered significant.
Conclusion
The inclusion of sumatriptan into cyclodextrin complexes increased its solubility and, consequently, improved its 
permeability through the biological membranes of a gastrointestinal tract model across an entire pH range of 1.2–
6.8. Changes in the physicochemical parameters of sumatriptan were reflected in its enhanced pharmacological 
in vivo activity in terms of the assessment of migraine pain and attendant symptoms. The antiallodynic action of a 
low dose (0.3 mg kg−1) of SUM-HPBCD observed in the von Frey test, similar to sumatriptan succinate and more 
effective than in its pure form, is in line with the results of the permeability experiments which showed superior 
permeability of SUM-HPBCD over the SUM-BCD form. Taken together, our present chemical and pharmaco-
logical study justifies the suggestion that the greater bioavailability of sumatriptan, in particular SUM-HPBCD, 
results from its inclusion into cyclodextrin structures.
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